Insurance clearance for cancer clinical trials participation: the Hopkins experience

Charles Rudin MD PhD Associate Director for Clinical Research Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins





SKCCC catchment area


SaTScan analysis

Geographic area covered

- 58 counties (MD, DE, DC, PA, VA, WV, NJ)
- Baltimore City is 18% of catchment area


Racial/ethnic diversity (N = 19,655)

- Black 18%
- White 79%
- Other 3%
- 1% Hispanic





Catchment area by race





Patient demographics 2005-07

Catchment Area					
	Baltimore City (%)	Non-BC Catchment (%)	Non-Catchment Area (%)	All (%)	
	N=1,952	N=11,145	N=4,540	N=17,637	
Race					
White	839 (43.0)	9468 (85.0)	4159 (91.6)	14466 (82.0)	
Black	1082 (55.4)	1229 (11.0)	245 (5.4)	2556 (14.5)	
Other	31 (1.6)	448 (4.0)	136 (3.0)	615 (3.5)	
Sex					
Male	973 (49.8)	6519 (58.5)	3311 (72.9)	10803 (61.3)	
Female	979 (50.2)	4626 (41.5)	1229 (27.1)	6834 (38.7)	
County poverty quartile					
1 (least)		9760 (87.6)	1372 (30.2)	11132 (63.1)	
2		996 (8.9)	1072 (23.6)	2068 (11.7)	
3		52 (0.5)	917 (20.2)	969 (5.5)	
4 (most)	1952 (100.0)	337 (3.0)	438 (9.6)	2727 (15.5)	
Participation in therapeutic clinical trials, by location					
	251 (12.8%)	2352 (21.1%)	666 (15.1%)	3269 (19%)	

Kanarek et al., JNCCN, 2010



Enrollment in clinical trials: 2005-07

Poisson multivariate model

		Therapeutic		Nontherapeutic	
		ACR*	p-Value	ACR*	p-Value
	<20	0.96	0.64	1.37	0.009
Age	20-64	1.00		1.00	
-	>64	1.12	0.002	0.87	0.007
	Male	1.00		1.00	
Sex	Female	1.33	<0.001	1.29	<0.001
) A (la :+ a	1.00		1.00	
_	White	1.00		1.00	
Race	Black	0.73	< 0.001	0.86	0.05
	Others	0.99	0.90	0.70	0.02
	<16.2	1.00		1.00	
County poverty, %	>16.2	1.14	0.10	0.88	0.31
Place of Residence					
Catchment area, non-BC		1.00		1.00	
Baltimore City		0.64	< 0.001	1.02	0.89
Non-Catchment Area		0.76	<0.001	0.72	<0.001

*accrual to case ratio



Clinical trials participation: taking into account race and residence

	Therapeutic		Non Therapeutic			
	Baltimore	Non-BC	Non-	Baltimore	Non-BC	Non-
	City	Catchment	Catchment	City	Catchment	Catchment
White	0.64 (0.52 <i>,</i> 0.79)	Reference	0.76 (0.70,0.84)	1.02 (0.76,1.38)	Reference	0.72 (0.63,0.81)
Black	0.47	0.73	0.56	0.88	0.86	0.62
	(0.38,0.58)	(0.65,0.82)	(0.48,0.65)	(0.65,1.20)	(0.74,1.00)	(0.51,0.76)
Other	0.64	0.99	0.75	0.71	0.70	0.50
races	(0.48,0.84)	(0.82,1.19)	(0.61,0.93)	(0.47,1.08)	(0.52,0.93)	(0.36,0.69)

Model includes age, sex, county poverty quartile and cancer site.



Does *insurance clearance* contribute to disparities in clinical trials accrual?

- Johns Hopkins Hospital Access Services
 - Confirms coverage for participation prior to clinical trials enrollment
 - Process initiated in July 2003
- Examined database from 2005 -2007
 - 4,617 patients referred all eligible for clinical trials
 - 490 cases denied
 - 138 cases without coverage for clinical trials
 - Total excluded from clinical trials = 628 cases



Demographics: approved and denied

Characteristic		Insurance clearance outcome		
		Approved	Denied	
A go	Median (yrs)	59.2	54.9	
Age	95% CI	57.8 - 60.5	53.6 - 56.2	
Sex	% female	42%	42%	
	White	83%	81%	
Race	Black	12%	13%	
	Other	5%	6%	




Time to coverage decision by outcome and by race

	Time to initial coverage decision (business days)	95% CI
Decision outcome		
Approved	5.51	4.93 - 6.09
Denied	5.98	5.28 - 6.67
Race		
White	5.8	5.34 - 6.39
Black	5.18	4.22 - 6.14
Other	5.29	3.76 - 6.83




Therapeutic clinical trial coverage, by trial type





Clinical trial coverage decision by state residency




 PA (unlike MD and VA) has no state law requiring insurance carriers to cover standard care costs associated with clinical trials

Klamerus et al., Clin Cancer Res 2010



Clinical trial coverage – state laws





Rates of approval by insurance provider

Insurance provider*	Cases	Final approval rate	Business days to complete review		
	reviewed (N)		Average	SD	
Medicare only	137	100%	2.8	2.6	
Medicare & secondary	769	100%	5.5	5.8	
Medicare & supplement	444	100%	3.3	2.5	
Johns Hopkins EHP	73	100%	6.1	4.0	
Aetna	278	98%	6.5	7.7	
United Healthcare	193	94%	6.1	5.4	
BC/BS DC	273	93%	6.7	4.7	
BC/BS Maryland	287	88%	4.3	3.7	
Cigna	110	86%	7.2	7.1	
Tricare	120	83%	7.0	4.5	
UHC Mamsi	239	82%	7.5	5.0	
Kaiser	74	81%	11.2	7.2	
Out-of-state BC/BS (not DC)	529	76%	7.6	7.3	
BC/BS NASCO	79	64%	4.2	2.4	
Other PPO	259	55%	7.8	7.1	
BC/BS Federal	250	46%	3.3	3.0	

* only companies reviewing over 70 cases are listed

Klamerus et al., *Clin Cancer Res* 2010